Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. - Wikidata - awgldk - TriplyDB

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

http://www.wikidata.org/entity/Q38042734

about

Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffold.Investigational drugs for treating psoriatic arthritis.Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases.Selective JAK inhibitors.Progress toward JAK1-selective inhibitors.Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells.

P2860

Q30385239-EDF6DA38-BAC8-4D97-87E0-9BD261DC6172 Q34677487-75C364CF-CB94-4134-BCAD-0C8D102E7CA8 Q38077992-2A4861FD-9F0D-4812-AA33-B3DAD7FF787C Q38097494-A0849868-6803-4576-A4E3-9575084C6BC0 Q38164828-101F699C-E7F9-4C41-B7B6-14AEEEE2E9FA Q38206551-CE8B4E61-DDFE-4B74-82AC-CDEF0AD3AD55 Q38251801-E5ACDE74-0E5B-49EF-8ED0-2D1C3BADACE2 Q38257749-7FABF796-AF49-484E-898D-D7B42D7E5CB5 Q38261371-A3D0FA17-9FEC-4623-8C37-64A29BBD7C00 Q38357083-9E0B9886-26CD-4218-9345-90D36C4201AE Q42227306-474EB8AA-F95E-4B8B-A4DA-2CB16E510E13 Q51318699-246CEA8A-EEA8-4CE1-B78E-D3BFFC0EA564

P2860

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

http://www.wikidata.org/entity/Q38042734

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

@en

type

label

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

@en

prefLabel

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

@en

P1433

Q38042734-59638EE4-2253-439C-A49C-B13EA9D86B37

P1476

Q38042734-7A8DAE40-8AD9-4362-AEFA-0DF43A2C69FD

P2093

Q38042734-1470EDAC-48F3-4DA7-B5B1-1362C5D6C4DD

P2860

Q38042734-0352DD7B-CBC7-475A-94B3-832A910C318A

Q38042734-1D4E4E87-999D-4B8A-959B-A5C8FE45799E

Q38042734-1DDA5A4E-D99D-4EDA-A960-9B89F4587C32

Q38042734-247C1375-FA49-4384-ABA3-2F93D95BF0B7

Q38042734-2EF4A966-345D-47A4-A708-1179AB18A45A

Q38042734-31AFF6BD-00A4-46EA-A942-7E805FE3BC5E

Q38042734-32C68D78-D24F-41F2-BFCC-5202EEAE9D3A

Q38042734-3415A6E1-1FE2-4B0D-A775-01F276F9DFC6

Q38042734-35331D0A-6FB7-4AF7-90F4-F4000A704E30

Q38042734-40CFDCC3-3009-4561-9446-78C8E00755D6

P304

Q38042734-4C887F36-4170-4623-BFE5-44C85CDB1913

P31

Q38042734-75B9D50B-DF8E-43D9-B997-C2DC6424B902

P356

Q38042734-3013FD59-84D9-4D3C-9729-21F5EF8913B1

P407

Q38042734-E50D235F-95A1-4FC9-A6CC-B0B57478DD1E

P433

Q38042734-0578632D-355E-42E3-AC81-74D7C19CDF45

P478

Q38042734-E8D73390-CD72-4A45-83E7-EB6B8C74B2E3

P577

Q38042734-7CFE66FF-05C2-418B-AD39-3A269E892219

P698

Q38042734-6A85E7A0-9634-43F0-A6AC-B4CE82F5E667

P921

Q38042734-7A9DC0C5-3113-4B73-8589-E6164F5D47A2

P356

13543776.2012.723693

P1433

Expert Opinion on Therapeutic Patents

P1476

Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.

@en

P2093

Peter Norman

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2

Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family

Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors

Thrombopoietin signal transduction requires functional JAK2, not TYK2

Jaks and STATs: biological implications

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice.

JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

P304

1233-1249

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2012.723693

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22971156

http://www.w3.org/2001/XMLSchema#string

P921